Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18-14/KM10B)

Sung Hoon Sim; Jeong Eun Kim; Min Hwan Kim; Yeon Hee Park; Jee Hyun Kim; Koung Jin Suh; Su-Jin Koh; Kyong Hwa Park; Myoung Joo Kang; Mi Sun Ahn; Kyoung Eun Lee; Hee-Jun Kim; Hee Kyung Ahn; Han Jo Kim; Keon Uk Park; Jae Ho Byun; Jin Hyun Park; Gyeong-Won Lee; Keun Seok Lee; Joohyuk Sohn; Kyung Hae Jung; In Hae Park

doi:10.1016/j.breast.2022.08.002

YUHSpace

BROWSE

0 170

Cited 3 times in

Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18-14/KM10B)

Authors: Sung Hoon Sim ; Jeong Eun Kim ; Min Hwan Kim ; Yeon Hee Park ; Jee Hyun Kim ; Koung Jin Suh ; Su-Jin Koh ; Kyong Hwa Park ; Myoung Joo Kang ; Mi Sun Ahn ; Kyoung Eun Lee ; Hee-Jun Kim ; Hee Kyung Ahn ; Han Jo Kim ; Keon Uk Park ; Jae Ho Byun ; Jin Hyun Park ; Gyeong-Won Lee ; Keun Seok Lee ; Joohyuk Sohn ; Kyung Hae Jung ; In Hae Park

Citation: BREAST, Vol.65 : 172-178, 2022-10

Journal Title: BREAST

ISSN: 0960-9776

Issue Date: 2022-10

MeSH: Antineoplastic Combined Chemotherapy Protocols / therapeutic use ; Biosimilar Pharmaceuticals* / therapeutic use ; Breast Neoplasms* / pathology ; Dioxolanes ; Female ; Humans ; Physicians* ; Receptor, ErbB-2 ; Trastuzumab

Full Text: https://www.sciencedirect.com/science/article/pii/S0960977622001333

DOI: 10.1016/j.breast.2022.08.002

Appears in Collections:: 1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

Yonsei Authors: Kim, Min Hwan(김민환) https://orcid.org/0000-0002-1595-6342
Sohn, Joo Hyuk(손주혁) https://orcid.org/0000-0002-2303-2764

URI: https://ir.ymlib.yonsei.ac.kr/handle/22282913/193377

사서에게 알리기

Show full item record Find it @ YMLIB

License

YUHSpace: Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18-14/KM10B)

YUHSpace

BROWSE

Browse

Links